EntryPoint Capital LLC Takes $528,000 Position in OrthoPediatrics Corp. (NASDAQ:KIDS)

EntryPoint Capital LLC acquired a new position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 22,793 shares of the company’s stock, valued at approximately $528,000.

Other large investors have also bought and sold shares of the company. Quest Partners LLC raised its stake in OrthoPediatrics by 924.4% during the third quarter. Quest Partners LLC now owns 11,986 shares of the company’s stock worth $325,000 after acquiring an additional 10,816 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in OrthoPediatrics during the 3rd quarter worth approximately $295,000. Charles Schwab Investment Management Inc. lifted its stake in OrthoPediatrics by 2.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 132,434 shares of the company’s stock valued at $3,590,000 after purchasing an additional 2,661 shares during the last quarter. Quantbot Technologies LP boosted its position in OrthoPediatrics by 42.2% in the third quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock valued at $157,000 after buying an additional 1,712 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of OrthoPediatrics by 125.1% during the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock worth $94,000 after buying an additional 1,929 shares during the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at OrthoPediatrics

In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the transaction, the general counsel now directly owns 110,767 shares in the company, valued at approximately $2,753,667.62. This represents a 4.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gregory A. Odle sold 5,359 shares of OrthoPediatrics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $133,224.74. Following the completion of the sale, the insider now owns 148,788 shares of the company’s stock, valued at $3,698,869.68. This represents a 3.48 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,732 shares of company stock valued at $589,978. Corporate insiders own 31.80% of the company’s stock.

OrthoPediatrics Price Performance

Shares of KIDS opened at $24.86 on Tuesday. The business has a 50-day moving average of $24.84 and a 200-day moving average of $25.37. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. The company has a market capitalization of $603.77 million, a price-to-earnings ratio of -20.21 and a beta of 1.22. OrthoPediatrics Corp. has a 1 year low of $21.02 and a 1 year high of $35.99.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The company had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. During the same period in the prior year, the firm posted ($0.23) EPS. As a group, equities research analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Analyst Ratings Changes

KIDS has been the topic of several recent research reports. Truist Financial cut their price objective on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Stifel Nicolaus reduced their price target on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a research report on Wednesday, March 5th.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.